Abstract 420TiP
Background
EGFR TKIs are established as an effective treatment for patients with EGFRm+ NSCLC harboring common mutations (Del19 or L858R). However, 7% to 23% of NSCLC tumors harbor uncommon EGFR mutations, where EGFR TKI efficacy is less established. Up to 75% of patients treated with afatinib develop T790M resistance. Second-line osimertinib is highly effective in these patients. In the GioTag study, sequential afatinib and osimertinib was associated with encouraging outcomes (median TTF and OS: 28.1 and 41.3 months, respectively) in 203 patients who developed T790M mutations after first-line therapy in a real-world setting.
Trial design
This real-world, non-interventional, global, multi-center study (UpSwinG; NCT04179890) will enroll ∼400 patients with EGFR TKI-naïve advanced (stage IIIB/IV) EGFRm+ NSCLC treated with EGFR TKIs across ∼65 study centers in ≤11 countries. Pre-existing data will be retrospectively collected from medical records (paper or electronic); selection bias will be minimized where possible, including by selecting only consecutive patients meeting each of the inclusion criteria and none of the exclusion criteria. The study comprises two cohorts (∼200 patients each). Cohort 1 will include patients with tumors harboring uncommon or compound EGFR mutations who received first- or second-line EGFR TKI treatment. Cohort 2 will include patients with common EGFR mutations who progressed on first-line afatinib, tested positive for T790M and were subsequently treated with second-line osimertinib (40 or 80 mg/day). Key exclusion criteria include prior participation in other EGFRm+ NSCLC studies and patients with active brain metastases. Across both cohorts, the primary objective will be time on treatment, defined from the start of EGFR TKI treatment until the end of EGFR TKI treatment or death by any cause in cohort 1, and from the start of first-line until the end of second-line treatment or death by any cause in cohort 2. Secondary objectives include overall response rate, overall survival, and time on second-line treatment (in cohort 1). Thus far, 256 patients have been recruited: 206 in cohort 1, and 50 in cohort 2.
Clinical trial identification
NCT04179890.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S. Miura: Advisory/Consultancy, Speaker Bureau/Expert testimony: Chugai Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Taiho Pharma; Speaker Bureau/Expert testimony: Ono Pharma; Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: Abbvie; Speaker Bureau/Expert testimony: Kyowa Hakko Kirin. A. Märten: Full/Part-time employment: Boehringer Ingelheim. S. Popat: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AZ; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Guardant Health; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Incyte; Honoraria (self), Advisory/Consultancy: Paradox; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Ariad.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session